Your browser doesn't support javascript.
loading
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases.
Trillo, Pamela; Sandoval, Josè; Trapani, Dario; Nicolò, Eleonora; Zagami, Paola; Giugliano, Federica; Tarantino, Paolo; Vivanet, Grazia; Ascione, Liliana; Friedlaender, Alex; Esposito, Angela; Criscitiello, Carmen; Curigliano, Giuseppe.
Affiliation
  • Trillo P; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, 20141 Milan, Italy; Department of Oncology and Hematology, University of Milan, 20122 Milan, Italy.
  • Sandoval J; Unit of Population Epidemiology, Division and Department of Primary Care Medicine, 1205 Geneva University Hospitals, Geneva, Switzerland; Department of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland.
  • Trapani D; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, 20141 Milan, Italy; Department of Oncology and Hematology, University of Milan, 20122 Milan, Italy.
  • Nicolò E; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, 20141 Milan, Italy; Department of Oncology and Hematology, University of Milan, 20122 Milan, Italy.
  • Zagami P; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, 20141 Milan, Italy; Department of Oncology and Hematology, University of Milan, 20122 Milan, Italy.
  • Giugliano F; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, 20141 Milan, Italy; Department of Oncology and Hematology, University of Milan, 20122 Milan, Italy.
  • Tarantino P; Breast Oncology Program, Dana-Farber Cancer Institute, 02115 Boston, USA; Harvard Medical School, 02115 Boston, USA.
  • Vivanet G; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, 20141 Milan, Italy; Department of Oncology and Hematology, University of Milan, 20122 Milan, Italy.
  • Ascione L; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, 20141 Milan, Italy; Department of Oncology and Hematology, University of Milan, 20122 Milan, Italy.
  • Friedlaender A; Department of Oncology, Geneva University Hospitals, 1205 Geneva, Switzerland.
  • Esposito A; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, 20141 Milan, Italy.
  • Criscitiello C; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, 20141 Milan, Italy; Department of Oncology and Hematology, University of Milan, 20122 Milan, Italy.
  • Curigliano G; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, 20141 Milan, Italy; Department of Oncology and Hematology, University of Milan, 20122 Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.
Eur J Cancer ; 185: 119-130, 2023 05.
Article in En | MEDLINE | ID: mdl-36989828
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Carcinoma, Lobular / Carcinoma, Ductal, Breast / Triple Negative Breast Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Eur J Cancer Year: 2023 Document type: Article Affiliation country: Italia Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Carcinoma, Lobular / Carcinoma, Ductal, Breast / Triple Negative Breast Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Eur J Cancer Year: 2023 Document type: Article Affiliation country: Italia Country of publication: Reino Unido